AstraZeneca has said a lab study of its Covid-19 antibody cocktail, Evusheld, found that the treatment retains neutralising activity against the Omicron coronavirus variant, showing promise for wider use of the therapy.
The study was conducted by independent investigators of the US Food and Drug Administration, the company said, according to Reuters.
AstraZeneca said more analyses of Evusheld against Omicron are being conducted by the company and third parties, with data expected “very soon”.
